UTMDHealthcare · Medical Instruments & Supplies

UTMD Stock Forecast: Utah Medical Products, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026

$72

+3.43% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 3 Nov 2026 — inside the top quartile.

Market cap

$199.4M

Ticker Nerd rank

77/ 100

Median analyst target

—

Analysts covering

Revenue$8.5M−14.3% y/y

Operating income$2.6M

Net income$2.7M

Free cash flow$1.2M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+5.2%

−2.3%

YTD

+31.2%

+26.8%

From 52W high

−5.5%

From 52W low

+37.2%

$53

$77

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

UTMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Utah Medical Products, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026

77/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility

Momentum

Issuance

Value

Size

Quality

Growth

Accruals

Revisions

Volatility (96): The share price has been relatively steady.

Revisions (25): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

UTMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on UTMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

UTMD appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

UTMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Utah Medical Products, Inc. returned +26.8% against +14.8% for the S&P 500, dividends included.

UTMD vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

UTMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Utah Medical Products, Inc. (UTMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 21.0×
Price / sales: 5.7×
Price / book: 1.8×
EV / EBITDA: 10.4×

Growth & margins

Revenue growth (YoY): −12.1%
Earnings growth (YoY): 5.9%
Gross margin: 55.8%
Operating margin: 34.8%
Net margin: 30.5%

Returns & dividend

Return on equity: 8.8%
Return on assets: 6.0%
Dividend yield: 1.8%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Utah Medical Products, Inc. (UTMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Utah Medical Products, Inc. has a market value of $199.4M and an enterprise value of $139.0M.
Revenue in the twelve months to 30 June 2026: $36.1M. The latest quarter shrank 12.1% year on year.
Net income over the same four quarters: $10.5M, a 29.0% net margin.
Diluted earnings per share, trailing twelve months: $3.28.
Free cash flow in the twelve months to 30 June 2026: $11.4M.
Utah Medical Products, Inc. spent $1.9M on share buybacks and $3.9M on dividends in the twelve months to 30 June 2026.
Shares outstanding: 3.2M.
Trailing P/E: 21.0×.
Forward dividend yield: 1.77%, paying out 38% of earnings.
Utah Medical Products, Inc. employs 140 people — $258K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

UTMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies

Company	Market cap	TKN rank
UTMDUtah Medical Products, Inc.	$199.4M	77
OSUROraSure Technologies, Inc.	$244.0M	77
PDEXPro-Dex, Inc.	$192.3M	95
SMTISanara MedTech, Inc.	$295.6M	91
KRMDKORU Medical Systems, Inc.	$142.4M	95
EMBCEmbecta Corp.	$360.1M	88
ZJYLJin Medical International Ltd.	$430.3M	14

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Utah Medical Products, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest UTMD news & analysis

UTMD's Q3 Earnings Rise Y/Y on Lower Costs, Orion Acquisition

Zacks Investment Research · 28 Oct 2026positive

Utah Medical Products reported Q3 earnings per share up 7% year over year despite a 12.1% revenue decline, with lower operating expenses helping earnings. Management expects a smaller revenue decline for full-year 2026.

Why it matters — The results highlight the contrast between declining revenue and improved earnings, alongside management’s outlook for a less pronounced full-year revenue decline.

UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026

Accesswire · 22 Oct 2026neutral

Utah Medical Products reported financial results for the third quarter and first nine months of calendar year 2026, including comparisons with the same periods in the prior year.

Why it matters — The report gives UTMD watchers an update on the company's recent financial performance and year-to-date results.

UTMD Trades at a Premium to the Industry: How to Play the Stock?

Zacks Investment Research · 8 Oct 2026positive

Zacks says Utah Medical Products’ Orion acquisition, strong cash reserves, improving margins and product expansion efforts support its growth prospects and continued shareholder returns.

Why it matters — These factors are relevant to UTMD watchers assessing the company’s business outlook and shareholder-return context.

Utah Medical Products, Inc. Extends Tender Offer

Accesswire · 5 Oct 2026neutral

Utah Medical Products, Inc. (Nasdaq:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The tender offer, initially scheduled to expire at 5:00 p.m. on October 5, 2026, has been extended.

Why it matters — The extension affects the timeline for UTMD shareholders considering participation in the company's share buyback offer.

Utah Medical Products, Inc. Clarifies Tender Offer Expiration Date

Accesswire · 25 Sept 2026neutral

Utah Medical Products, Inc. announced details of a tender offer to purchase up to 650,000 shares of its common stock at $75.00 per share, as outlined in its SEC Form TO filing. The offer is scheduled to expire at 5:00 p.m., and the company clarified this expiration date in the announcement.

Why it matters — UTMD watchers would care because the clarified tender offer expiration date affects the timeline for shareholders deciding whether to participate in the share repurchase.

FAQ

Frequently asked questions about UTMD stock

How does Ticker Nerd's model rank UTMD?

As at 3 Nov 2026, Utah Medical Products, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).

What is the UTMD stock forecast for 2030?

No analyst covering Utah Medical Products, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UTMD are extrapolating price history, which says nothing about the business.

How has UTMD stock performed over the past year?

Utah Medical Products, Inc. returned +26.8% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Utah Medical Products, Inc. do?

Utah Medical Products, Inc. is a medical device company that develops, manufactures, and markets specialized disposable and reusable products for healthcare settings.

What is the latest news on UTMD?

The most recent item we track (Zacks Investment Research, 28 Oct 2026): "UTMD's Q3 Earnings Rise Y/Y on Lower Costs, Orion Acquisition". Utah Medical Products reported Q3 earnings per share up 7% year over year despite a 12.1% revenue decline, with lower operating expenses helping earnings. Management expects a smaller revenue decline for full-year 2026.

Company

About Utah Medical Products, Inc.

Utah Medical Products, Inc. is a medical device company that develops, manufactures, and markets specialized disposable and reusable products for healthcare settings. The company focuses on women’s and babies’ health, with offerings used in obstetrics, gynecology, neonatal care, perinatology, urology, blood pressure monitoring, and blood collection. Its product portfolio includes labor and delivery tools, fetal monitoring accessories, vacuum-assisted delivery systems, infant respiratory hoods, and electrosurgical devices. Utah Medical Products serves hospitals, clinics, and other medical facilities that require procedure-specific devices designed for clinical use and patient safety. Headquartered in Midvale, Utah, the company operates as a focused supplier within the broader medical instruments and supplies market, with products distributed across domestic and international healthcare markets.

CEO Mr. Kevin L. Cornwell · 140 employees · United States · https://www.utahmed.com